RSS-Feed abonnieren
DOI: 10.1055/s-0040-1718873
Platelet Function and Turnover in Essential Thrombocythemia: A Systematic Review
![](https://www.thieme-connect.de/media/sth/202101/lookinside/thumbnails/10-1055-s-0040-1718873_02791-1.jpg)
Abstract
Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by increased platelet counts. ET has an incidence of 0.6 to 2.5 per 100,000 per year in Europe and North America. The disease is characterized by an increased thromboembolic risk, possibly caused by increased platelet counts. Furthermore, increased platelet function and/or increased platelet turnover may play a role. We aimed to explore: (1) whether platelet function and platelet turnover are increased in ET patients compared with healthy controls, and (2) whether these parameters are associated with increased thromboembolic risk and, therefore, may support decision-making on treatment in ET patients. We performed a systematic literature search on March 20, 2020 in Embase and PubMed following the Preferred Reporting Items for Systematic and Meta-Analysis (PRISMA) guidelines. In total, 1,923 articles were identified, 38 of which were included according to prespecified inclusion and exclusion criteria. Among the 38 studies, platelet activation (CD36 and CD62P) was investigated in 18 studies and was found to be increased in 12 of these. Platelet aggregation was investigated in 21 studies and was reported to be reduced in 20 of them. Platelet turnover (immature platelet count and mean platelet volume) was investigated in five studies with inconclusive results. No parameters were reported to predict the risk of thromboembolic events. In conclusion, platelet activation was increased in ET patients, but platelet aggregation was reduced. Future studies exploring markers of thromboembolic risk in ET patients are warranted.
Keywords
biomarker - essential thrombocythemia - platelet activation - platelet aggregation - platelet turnoverPublikationsverlauf
Artikel online veröffentlicht:
01. Februar 2021
© 2021. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Pedersen OH, Larsen ML, Grove EL. et al. Platelet characteristics in patients with essential thrombocytosis. Cytometry B Clin Cytom 2018; 94 (06) 918-927
- 2 Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 1991; 67 (11) 2926-2930
- 3 Reményi G, Szász R, Debreceni IB. et al. Comparison of coated-platelet levels in patients with essential thrombocythemia with and without hydroxyurea treatment. Platelets 2013; 24 (06) 486-492
- 4 Fabris F, Randi ML. Essential thrombocythemia: past and present. Intern Emerg Med 2009; 4 (05) 381-388
- 5 Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC. et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol 2009; 84 (02) 102-108
- 6 Niittyvuopio R, Juvonen E, Kekomäki R, Oksanen K, Anttila P, Ruutu T. The predictive value of megakaryocytic and erythroid colony formation and platelet function tests on the risk of thromboembolic and bleeding complications in essential thrombocythaemia. Eur J Haematol 2004; 72 (04) 245-251
- 7 Raszeja-Specht A, Skibowska A, Bieniaszewska M, Szutowicz A. Relationships between thrombohemorrhagic complications and platelet function in patients with essential thrombocythaemia. Am J Hematol 2001; 68 (01) 32-36
- 8 Ayer M, Menken İ, Yamak M, Ayer FA, Kırkızlar O, Burak Aktuğlu M. The impact of mean platelet volume (MPV) and JAK-2 mutation on thrombosis in chronic myeloproliferative diseases. Indian J Hematol Blood Transfus 2017; 33 (02) 181-187
- 9 Rinder HM, Schuster JE, Rinder CS, Wang C, Schweidler HJ, Smith BR. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood 1998; 91 (04) 1288-1294
- 10 Kissova J, Bulikova A, Ovesna P, Bourkova L, Penka M. Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms. Int J Hematol 2014; 100 (05) 429-436
- 11 Pedersen OH, Larsen ML, Kristensen SD, Hvas AM, Grove EL. Recurrent cardiovascular events despite antiplatelet therapy in a patient with polycythemia vera and accelerated platelet turnover. Am J Case Rep 2017; 18: 945-948
- 12 Tran JQD, Pedersen OH, Larsen ML. et al. Platelet microRNA expression and association with platelet maturity and function in patients with essential thrombocythemia. Platelets 2020; 31 (03) 365-372
- 13 Fabris F, Randi M, Sbrojavacca R, Casonato A, Girolami A. The possible value of platelet aggregation studies in patients with increased platelet number. Blut 1981; 43 (05) 279-285
- 14 Musolino C, Alonci A, Bellomo G. et al. Markers of endothelial and platelet status in patients with essential thrombocythemia and polycythemia vera. Hematology 2000; 4 (05) 397-402
- 15 Cacciola RR, Di Francesco E, Pezzella F, Tibullo D, Giustolisi R, Cacciola E. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia. Acta Haematol 2007; 118 (04) 215-218
- 16 Pareti FI, Gugliotta L, Mannucci L, Guarini A, Mannucci PM. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders. Thromb Haemost 1982; 47 (02) 84-89
- 17 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6 (07) e1000097
- 18 Presseizen K, Friedman Z, Shapiro H, Radnay J, Ellis MH. Phosphatidylserine expression on the platelet membrane of patients with myeloproliferative disorders and its effect on platelet-dependent thrombin formation. Clin Appl Thromb Hemost 2002; 8 (01) 33-39
- 19 Thibert V, Bellucci S, Cristofari M, Gluckman E, Legrand C. Increased platelet CD36 constitutes a common marker in myeloproliferative disorders. Br J Haematol 1995; 91 (03) 618-624
- 20 Coucelo M, Caetano G, Sevivas T. et al. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients. Int J Hematol 2014; 99 (01) 32-40
- 21 Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res 2002; 108 (2-3): 139-145
- 22 Wehmeier A, Tschöpe D, Esser J, Menzel C, Nieuwenhuis HK, Schneider W. Circulating activated platelets in myeloproliferative disorders. Thromb Res 1991; 61 (03) 271-278
- 23 Bermejo E, Alberto MF, Meschengieser SS, Lazzari MA. Assessment of platelet activation in myeloproliferative disorders with complementary techniques. Blood Coagul Fibrinolysis 2004; 15 (03) 235-240
- 24 Zahavi J, Zahavi M, Firsteter E, Frish B, Turleanu R, Rachmani R. An abnormal pattern of multiple platelet function abnormalities and increased thromboxane generation in patients with primary thrombocytosis and thrombotic complications. Eur J Haematol 1991; 47 (05) 326-332
- 25 Wehmeier A, Scharf RE, Fricke S, Schneider W. Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease. Haemostasis 1989; 19 (05) 251-259
- 26 Bazzan M, Tamponi G, Schinco P. et al. Platelet behavior in essential thrombocythemia: a study of 31 cases. Eur J Haematol 1989; 43 (04) 350-351
- 27 Castaman G, Lattuada A, Ruggeri M, Tosetto A, Mannucci PM, Rodeghiero F. Platelet von Willebrand factor abnormalities in myeloproliferative syndromes. Am J Hematol 1995; 49 (04) 289-293
- 28 Rocca B, Ciabattoni G, Tartaglione R. et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost 1995; 74 (05) 1225-1230
- 29 Meschengieser S, Blanco A, Woods A. et al. Intraplatelet levels of vWF:Ag and fibrinogen in myeloproliferative disorders. Thromb Res 1987; 48 (03) 311-319
- 30 Tsantes AE, Dimoula A, Bonovas S. et al. The role of the Platelet Function Analyzer (PFA)-100 and platelet aggregometry in the differentiation of essential thrombocythemia from reactive thrombocytosis. Thromb Res 2010; 125 (02) 142-146
- 31 Cesar JM, Pallares E, Rubí J, Navarro JL. Lactate production by thrombin-activated platelets of patients with primary thrombocythemia. Thromb Res 2006; 118 (03) 335-339
- 32 Zeidman A, Horowits A, Kanter P. et al. Platelet function and its clinical significance in the myeloproliferative disorders. HAEMA 2005; 8 (01) 64-69
- 33 Mayordomo O, Cárcamo C, Vecino AM, Navarro JL, Cesar JM. Arachidonic acid metabolism in platelets of patients with essential thrombocythaemia. Thromb Res 1995; 78 (04) 315-321
- 34 Schlemper RJ, van der Maas APC, Eikenboom JCJ. Familial essential thrombocythemia: clinical characteristics of 11 cases in one family. Ann Hematol 1994; 68 (03) 153-158
- 35 McIntyre KJ, Hoagland HC, Silverstein MN, Petitt RM. Essential thrombocythemia in young adults. Mayo Clin Proc 1991; 66 (02) 149-154
- 36 Hehlmann R, Jahn M, Baumann B, Köpcke W. Essential thrombocythemia. clinical characteristics and course of 61 cases. Cancer 1988; 61 (12) 2487-2496
- 37 Bellucci S, Janvier M, Tobelem G. et al. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 1986; 58 (11) 2440-2447
- 38 Barbui T, Bassan R, Viero P, Cortelazzo S, Dini E. Platelet function after busulphan in chronic myeloproliferative disorders. Haematologica 1983; 68 (04) 469-477
- 39 Hoagland HC, Silverstein MN. Primary thrombocythemia in the young patient. Mayo Clin Proc 1978; 53 (09) 578-580
- 40 Hussain S, Schwartz JM, Friedman SA, Chua SN. Arterial thrombosis in essential thrombocythemia. Am Heart J 1978; 96 (01) 31-36
- 41 Kanya P, Rattarittamrong E, Wongtakan O. et al. Platelet function tests and inflammatory markers for the differentiation of primary thrombocytosis and secondary thrombocytosis. Asian Pac J Cancer Prev 2019; 20 (07) 2079-2085
- 42 Mitus AJ, Barbui T, Shulman LN. et al. Hemostatic complications in young patients with essential thrombocythemia. Am J Med 1990; 88 (04) 371-375
- 43 Barbui T, Finazzi G, Carobbio A. et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120 (26) 5128-5133 , quiz 5252
- 44 Tefferi A, Guglielmelli P, Larson DR. et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014; 124 (16) 2507-2513 , quiz 2615
- 45 Klampfl T, Gisslinger H, Harutyunyan AS. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369 (25) 2379-2390
- 46 Tefferi A, Lasho TL, Finke CM. et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv 2016; 1: 105-111
- 47 Neergaard-Petersen S, Hvas AM, Kristensen SD, Grove EL. Platelets and antiplatelet therapy in patients with coronary artery disease and diabetes. Semin Thromb Hemost 2016; 42 (03) 234-241
- 48 Lancellotti S, Dragani A, Ranalli P. et al. Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. J Thromb Haemost 2015; 13 (07) 1226-1237
- 49 Rottenstreich A, Kleinstern G, Krichevsky S, Varon D, Lavie D, Kalish Y. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. Eur J Intern Med 2017; 41: 49-54